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g lobu linem ia  D Syndrom e: Two D iseases w ith  D istinct 
C linical, Serologic, a n d  G enetic F eatu res
AVI LIVNEH, JOOST P.H. DRENTH, INA S. K LASEN, PN IN A  LANG EVITZ, JACOB GEORGE, DAVID A. SHELTON, 
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ABSTRACT Objective. To determine whether the 2 periodic febrile syndromes familial Mediterranean fever
(FM F) and hyperim m unoglobulinem ia D syndrome (H IDS) are distinct diseases.
Methods. C linical manifestations o f  the diseases were analyzed by physicians experienced with 
F M F  and HIDS. Serum im m unoglobulin (Ig) levels were studied in 70 patients with F M F  using 
nephelometry or E L I S A  and compared with Ig levels in 50 patients with HIDS. Genetic  linkage o f  
H ID S with the chrom osom e 16 polym orphic locus R T 70, currently used for refined localization o f  
the F M F  susceptibility gene (M E F V ),  was studied in 9 H ID S fam ilies ( 18 patients) using polym erase 
chain reaction amplification and gel electrophoresis.
Results. The main clinical features distinguishing F M F  from H ID S were lymphadenopathy, skin 
eruption, and symmetrical oligoarthritis in H ID S, and monoarthritis, peritonitis, and pleuritis in 
FMF. Increased IgG  levels were found in 12 patients with F M F  ( 17%), Ig A  in 16 (23% ), IgM  in 9 
( 13% ), and IgD in 9 ( 13% ), significantly low er than the prevalence reported for H ID S. We found no 
evidence for genetic linkage between H ID S and the chrom osom e 16 marker R T 70 .
Conclusion. H ID S and F M F  are different entities, clinically, im m unologically, and genetically.
{J Rheumatol 1997;24:1558-63)
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F A M I L I A L  M E D I T E R R A N E A N  F E V E R  H Y P E R I M M U N O G L O B U L I N E M I A  D S Y N D R O M E  
Ig A  IgD  C H R O M O S O M E  16 M E F V
Familial Mediterranean fever (FM F) is an autosomal reces­
sive disease characterized by recurrent episodes o f  febrile 
serositis, m ostly  peritonitis, arthritis, and p leuritis'. 
Although im m unologic, serologic, and m etabolic factors 
have been studied2-9, the pathogenesis o f  FMF is still not 
known. The recent mapping o f  the FM F susceptibility gene, 
designated MEFV, to chrom osom e 16p10, permits elucida-
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tion o f the m olecular lesion underlying the disease by posi­
tional cloning.
H yperim m unoglobu linem ia D syndrom e (H ID S) is 
another autosomal recessive periodic febrile syndrome, 
characterized by febrile attacks o f  abdominal and joint 
pain". W hile its resem blance to FM F is striking, there arc 
suggestions that it is a clinically, serologically, and geneti­
cally distinct en tity11-13. H owever, more data to support 
H ID S’s uniqueness are required, as studies distinguishing  
the 2 diseases are lim ited and based on a small population of 
patients with FM F11. M oreover, progressive narrowing of 
the FMF candidate interval permits reexamination o f genet­
ic linkage data on HIDS fam ilies. An earlier study12 used 
haplotype analysis with 4 markers from M EFV region of 
chrom osom e 16p, but the closest marker on the centromeric 
side o f  M EFV was roughly 10 cM  from the gene. We took 
advantage o f  a new ly identified marker about 1 cM  cen­
tromeric to M EFV to perform linkage studies in HIDS fam­
ilies. In addition, we established a collaborative study 
am ong our centers to compare the clinical and im m unologi­
cal features o f FM F and HIDS.
MATERIALS AND METHODS
Comparative analysis o f clinical manifestations. Representatives of the 
FM F clinic o f  Sheba Medical Center and the HIDS clinic at the University 
Hospital o f  Nijmegen and the HIDS study group who personally attend 
patients with the diseases met at Nijmegen to study the manifestations of
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the 2 diseases for similarities and differences by reviewing and discussing 
the clinical presentation o f  the diseases. The analysis was based on experi­
ence with 50 patients with HIDS treated by physicians o f  the hyper-IgD 
study group for the last 15 years, and about 4000 patients with FM F fol­
lowed over the last 40 years as part o f  an ongoing study in the FM F clinic. 
Clinical features o f  these patients have been reported111,14,15 and recently 
updated13,16.
Determination and comparative analysis o f  immunoglobulin levels. 
Seventy consecutive patients with FMF, attending the FM F clinic for rou­
tine followup examination, donated 10 ml blood. All were following a con­
tinuous colchicine regimen. Before starting colchicine all had clinical m an­
ifestations agreeing with the criteria for F M F 117. At the time of blood dona­
tion, they were free o f  attacks. No patient had, in addition to FMF. a rec­
ognized acute or chronic allergic, inflammatory, or infectious condition 
leading to hyperglobulinemia. After clot formation, the serum was separat­
ed and kept at - 2 0  C until studied.
IgD level was studied by ELISA as describedls. Briefly, microtiter 
plates were coated with rabbit antihuman IgD antibody, and sera and stan­
dard solutions with known concentrations of IgD as reference were added. 
The presence of IgD was detected by addition o f  monoclonal IgG antihu­
man IgD followed by peroxidase conjugated, antimouse IgG and substrate. 
The absorbency was read using an ELISA reader and the level o f  IgD in 
sera was determined with reference to the standard solutions. Levels o f  the 
IgG, IgM, and IgA were studied using nephelometry (Cobas Fara, Roche 
Diagnostics, Basel, Switzerland). The immunoglobulin levels in 70 FMF 
and 50 HIDS sera were compared. Ig levels in HIDS sera were determined 
previously by the same laboratory, personnel, and methodology as in the 
current study and were reported as part o f  a large clinical and laboratory 
study o f  these patients13.
Determination o f the linkage between HIDS and RT70. DNA samples were 
obtained from members of  9 HIDS families, consisting of 18 patients and 
26 first degree relatives. Their pedigrees and genomic DNA preparation 
have been reported12. The diagnosis o f  HIDS was made according to pub­
lished criteria12. These families were genotyped for a newly described 
tetranucleotide-repeat marker derived from cosmid RT70, which is located 
within 1 cM of M EFV on chrom osom e 16p. Five alleles o f  this marker 
were identified in the general population19.
RT70 polymerase chain reaction (PCR) primers were synthesized as 
follows: 5 ,-T C A C T C T A G C T T G G G T G A A G G -3 ' and 5 '-C C T C T C C A - 
G A G G A C A A C T G G -3 '.  The PCR reactions were carried out in a volume 
if  10 pi. The reaction mixture consisted o f  the pair o f  primers (0.1 pi o f  150 
ig/pl each), [32P] labeled primer [0.05 pi from a 15 pi reaction mix con- 
aining 187.5 ng 5 ' primer, 7.5 pi gam m a-[32P]-ATP (DuPont, Boston. MA, 
USA; 10 mCi/ml), 1.5 pi T4-polynucleotide kinase (Promega, Madison, 
vVI, USA; 10 U/pl), 10 x  buffer and H ,0 ] ,  genomic DNA ( 1-2 pi contain- 
ng 2 5 -5 0  ng), deoxynucleosides triphosphate (GeneAm p dNTPs, Perkin 
ilmer, Branchburg, NJ, USA; 2 pi o f  a mixture containing 2 pg/ml o f  each 
)f the 4 nucleosides), Taq polymerase (0.24 pi o f  10 U/pl), 10 x  buffer and 
-1,0. The PCR program consisted o f  30 cycles of  1 min denaturing at 94°C, 
min annealing at 55°C, and I min extension at 72°C. The reaction was 
topped with 7 pi loading/stop buffer (formamide, 0.1% xylene cyanol, 
). 1% bromophenol blue, and 2% 0.5 M EDTA).
Electrophoresis o f  the PCR products was carried out in acrylamide 
equencing gels at 1800 V for 3 h. The gel was dried and exposed to film, 
.od scores defined as logarithm to the base 10 o f  the ratio o f  odds in favor 
>f linkage to the odds against linkage between RT70 and HIDS were cal- 
ulated using the LIN K A G E programs, assuming a recessive model o f  
1IDS inheritance and a gene frequency of 0.001.
tatistical analysis. Statistical analysis was performed using the chi- 
quared method or S tudent’s t test, indicated in Results.
of FMF and HIDS is shown in Table 1. The 2 diseases 
appear to be distinct in most aspects, including the duration 
of the attack, the temperature curve, the organs involved and 
the nature of the involvement, the response to treatment, and 
the prognosis. A typical attack of FMF lasts 2 -4  days and is 
characterized by a temperature curve with a fast rise, plateau 
and abrupt fall, peritonitis, pleuritis or monoarthritis, possi­
bly erysipelas-like eruption, and virtually no other dermal 
manifestations or lymphadenopathy (rarely, if ever, in chil­
dren). On the other hand attacks of HIDS are marked by 
longer duration (around a week), gradual defervescence 
(lysis), common occurrence of lymphadenopathy and rash, 
and abdominal pain, which very infrequently develops into 
acute abdomen and symmetrical oligoarthritis or arthralgia. 
Amyloidosis, a life threatening manifestation of FMF, has 
not been noted in HIDS, and colchicine, while very effective 
in FMF, is less effective in HIDS. Additional dissimilarities 
exist, as outlined in Table 1.
Serological analysis. Results of Ig analysis in patients with 
FMF are presented in Tables 2^4. As shown in Tables 2 and
3, abnormally elevated levels of Ig of at least one isotype 
were noted in 34 of 70 patients (49%). Sixteen patients 
(23% of all patients and 47% of patients with increased Ig 
levels) had elevated IgA. Elevated IgM levels were noted in
9 patients (13%), IgG in 12 (17%), and IgD in 9 (13%). In
10 patients, the increased IgA level was associated with a 
concomitant rise of IgG (5 patients), IgD (4 patients), or IgD 
plus IgM (one patient). As a group, however, patients with 
FMF exhibited normal Ig levels between the attacks (Table
4, mean values in FMF).
All 9 patients with FMF (4 men and 5 women) who dis­
played elevated levels of IgD appeared to have classic FMF 
with attacks of peritonitis (9 patients), monoarthritis (7 
patients), and pleuritis (3 patients), and had none of the spe­
cific HIDS clinical features delineated in the previous sec­
tion. All were colchicine responsive and did not have skin 
manifestations or lymphadenopathy. Compared to patients 
with HIDS, patients with FMF had significantly lower rates 
of elevated individual Ig levels (Table 3), and significantly 
lower mean IgA and IgD levels (Table 4). Therefore, in 
addition to differences in IgD, the prevalence of elevated Ig 
levels and mean IçA levels also differentiate the disease.cr
Molecular analysis. A panel of 9 HIDS families was geno­
typed for the RT70 marker, which is about 1 cM centromeric 
to the FMF susceptibility gene on chromosome 16p. Lod 
scores between HIDS and RT70 are shown in Table 5. Total 
lod scores of < -2  were obtained up to recombination fre­
quency of 0.03, excluding HIDS from the interval within 3 
cM of RT70. Moreover, haplotype analysis, using RT70 typ­
ings in conjunction with 4 other markers12, also rules out the 
placement of HIDS in the MEFV region of chromosome 16.
Œ SU LTS
7inical analysis. The comparison of clinical manifestations
DISCUSSION
Although FMF and HIDS share certain features, we
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Tabic I. FM F and HIDS are clinically distinct.
Manifestation FM F HIDS
Age of onset Usually before age 20 Childhood (70% before 
1st year o f  life)
Duration of 1 —4 days 3 -7  days
attack
Fever Begins and ends abruptly. Sudden rise. Gradual
The temperature curve is o f decrease. Chills are comm on
continuous type. Chills are com m on
Abdominal Occur in most patients. Occurs in most patients;
attacks Diffuse, or less frequently usually pain alone.
localized. Peritoneal Acute abdomen (in
irritation is the rule. < 10%). Diarrhea
Diarrhea is not com m on (5%) very com m on (80%)
Joint attacks Presents as monoarthritis Presents as symmetric
o f  the large jo ints of oligoarthritis o f
lower extremities (75%). large joints o f
Polyarthralgia maym W V lower extremities.
occasionally accompany Art lira lui a is veryW  *
febrile attacks elsewhere. frequent. No chronic
Chronic joints and joint disease found
spondyloarthropathy are rare
(< 5% and < 1%. respectively)
Thoracic Pleuritis is com m on (25%), Not found
attacks unilateral. Pericarditis is 
rare (< 1%)
Rash Rare (< 5%). Only Very com m on (90%).
erysipeloid. Those affected Types o f  rash: macular,
experience only rare mac u 1 opap u 1 ar, pu rp u ra .
episodes during lifetime Pathology: vasculitis
“Orchitis” Rare (< 5%). Unilateral.
Only in childhood and adolescence. Rare 
episodes during lifetime
Not found
Muscle pain Short or prolonged episodes 
of febrile myalgia are uncommon. Afebrile 
muscle pain o f  lower extremities, usually 
provoked by exertion, is com m on (30%)
Rare
Lymphadenopathy Questionable in early Generalized and
childhood cervical. Very com m on (> 90%)
Splenomegaly In about 30% o f  patients In about 50% of patients
Amyloidosis Develops in many untreated patients Not found
Vasculitis Hypersensitivity, GN,
PAN are more com m on compared to population 
not affected by FM F
Skin eruption
Genetic origins. Autosomal recessive. The Autosomal recessive.
populations susceptibility gene is Chromosomal location is
mapped to chrom osom e 16p. not known. Occurs in
Sephardi Jews, Armenians. Arabs, and Turks Western Europeans
W B C in attack Increased 1ncreased
ESR in attack Increased Increased
Hematuria Com m on (5%) Present in 20%
Synovial fluid Turbid, inflammatory; 
white cell count > 20,(K)()/(jl
Turbid, inflammatory
Colchicine treatment Prevents attacks and amyloidosis Usually not effective
WBC: white blood cells; ESR: erythrocyte sedimentation rate: GN: glomerulonephritis; PAN: polyarteritis 
nodosa.
observed that the 2 d iseases differ in their clinical m anifes­
tations, serum Ig concentrations, and genetics. Lympha­
denopathy, certain types o f rash, and sym m etric oligoarthri­
tis are ex c lu s iv e ly  found in H ID S, w hile peritonitis,
monoarthritis, and pleuritis are typical to FMF (Table 1). 
Increased levels o f  IgG, IgM, IgA, and IgD have a much 
lower prevalence in FMF compared with prevalence report­
ed in HIDS (Tables 2, 3, 4). Finally, m olecular analysis,
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Table 2. Patients with FM F with elevated immunoglobulin levels*.
Patient
IgG
(6 .5-15.2
g/l)
Immunoglobulin
IgA
(1.1-3.75
g/l)
Levels
IgM
(0 .5-2
g/l)
IgD
(< 100 
U/ml
3 20.96 1.23 2.0 20
6 14.18 2.63 3.21 < 5
7 12.47 5.92 2.0 57
8 14 6.36 1.46 80
9 16.96 1.74 2.16 51
11 9.06 6.64 1.48 182
13 9.86 2.75 2.12 28
14 15.54 1.89 0.94 54
15 29.22 5.96 1.91 17
16 13.87 2.42 2.0 696
18 13.25 2.42 2.26 60
19 11.65 6.24 1.07 17
21 12.08 1.77 2.5 58
23 15.5 3.68 1.58 38
27 15.08 8.53 0.76 60
29 16.2 4.14 1.98 3
35 15.08 5.99 1.66 174
36 11.1 1.28 i 44 f  f 19
37 16.56 1.68 0.61 19
38 14.4 4.79 1.92 225
41 8.6 7.1 1.42 226
43 15.33 3.34 0.98 59
48 13.29 4.55 3.63 146
49 10.32 3.92 0.66 10
55 12.15 6.1 2.0 52
57 18.2 2.99 1.93 45
58 16.14 6.71 0.48 44
60 13.3 3.79 0.8 312
61 12.3 3.67 0.57 190
62 15.20 3 2.8 148
64 9.5 2.89 3.51 64
65 16.28 8.86 0.86 73
67 15.86 4.06 1.98 4
70 15.19 3.70 1.98 49
*Ig levels were determined in 70 patients by nephelometry (IgG. A. M) and ELISA (IgD). Data are from patients 
with increased titers in at least one type o f  Ig (shown in boldface type).
Table 3. Prevalence o f  elevated immunoglobulins in FMF (70 patients) and 
HIDS (50 patients). Immunoglobulins were determined using nephelom e­
try (IgG. IgA. IgM) or ELISA (IgD). Results for patients with FM F are 
shown in Table 2; for HIDS in reference13.
Immunoglobulin No. (%) o f  Patients p*
FM F HIDS
IgA 16(23) 4 2 (8 2 ) < 0.001
IgG 12(17) 19 (38) < 0 .0 2
IgM 9 ( 1 3 ) 17(34) <0 .01
IgD 9 ( 1 3 ) 50 (100) <0 .001
Any Ig 34 (49) 50 (100) <0 .001
*Chi-squared test.
Table 4. Mean immunoglobulin levels in FM F (70 patients) and HIDS (50 
patients). Immunoglobulins were determined using nephelometry (IgG. 
IgA. IgM) or ELISA (IgD). Mean Ig levels were computed based on Ig 
determination in sera of  70 patients with FM F (Table 2) and from refer­
e n ce13 (50 patients with HIDS).
Immunoglobulin Normal Mean Ig level p*
(g/l) FM F HIDS
IüA
G
1.1-3.75 3.12 5.54 < 0 .001
IgG 6.50-15 .20 12.76 13.5 NS
IgM 0.50-2 .00 1.47 1.42 NS
IgD < 100 U/ml 57.22 1158 < 0.001
^Student’s t test. NS: not significant.
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Table 5. Linkage between RT70 and HIDS.
Recombination Fraction 
0.00 0.01 0.02 0.03 0.04 0.05 0.06
Lod score* -oo -3 .8 5  -2 .7 2  -2 .0 8  -1 .65 -1 .33 -1 .0 8
*Lod scores o f  9 families with one or more progeny with HIDS. Lod scores 
were computed using LIN K A G E programs.
using the RT70 marker, confirmed that the HIDS locus is not 
linked to the FMF susceptibility gene on chromosome 16p 
(Table 5).
FMF and HIDS differ clinically in almost every aspect 
studied (Table 1). However, as some overlap does occur, 
recurrent painful febrile attacks may still constitute a diag­
nostic challenge. The clue for correct diagnosis is the pres­
ence of the pathognomonic manifestations outlined above. 
In addition, the origin of the patient is also helpful, as 
patients with HIDS and FMF stem from different popula­
tions (Table 1). Despite serologic characterization of HIDS 
and significant advancement toward the detection of MEFV, 
the diagnosis of the 2 conditions currently still relies on clin­
ical evidence.
Genetic evidence also strongly supports the view that 
FMF and HIDS are distinct entities. That these diseases are 
common in different populations suggested a different 
genetic basis, although there remained the possibility that 
the 2 disorders could be allelic mutations at the same locus. 
However, our present data, coupled with the previous study 
from Drenth, el cil]2, indicates that the HIDS susceptibility 
gene is not linked to the MEFV region of chromosome 16. 
The chromosomal location of the HIDS susceptibility locus 
remains unknown.
Studies focusing on Ig of various isotypes in FMF are 
scarce and report conflicting results. One study showed ele­
vation of IgG, IgM, and IgA during attacks and remissions 
in untreated patients and in patients taking colchicine20. A 
study performed before the era of colchicine use found that 
only the IgG and IgM levels were invariably increased; the 
IgA levels were constantly low (reviewed in 2()). A third 
study showed normal IgG, IgM, and IgA in colchicine treat­
ed patients with FMF21. Our results agree with the latter, 
showing normal mean Ig levels in patients with FMF (Table 
4), but also show that about half the patients may display an 
elevated level of Ig of one or more isotypes (Table 3). 
Differences with other studies may stem from variance in 
methodology. Our use of modern automated techniques of 
immunoglobulin determination, combined with our com­
mon experience of normal Ig levels obtained on multiple 
occasions, supports our results.
Our findings have an important consequence: while vir­
tually all patients with HIDS display high concentrations of 
IgD 11,13, the opposite is not true; the finding of elevated lev­
els of IgD in a patient with periodic fever is not necessarily 
diagnostic of HIDS. About 13% of our patients with FMF
had elevated IgD titers, half of them with levels higher than 
twice the normal upper limit (> 200 U/ml, Table 2). The rea­
son for increased IgD in 13% of patients with FMF is not 
clear. None of these patients with FMF had specific mani­
festations of HIDS. In the normal population IgD has a tri- 
modal distribution pattern with a 95% confidence interval 
from 0.19 to 156 U/ml22. It is possible that the high IgD 
values in some patients with FMF reflect the high end of the 
normal distribution.
The finding that IsA levels are elevated in a considerablecr ^
number of patients with FMF is novel and interesting: FMF 
has been associated with increased prevalence of Henoch- 
Schönlein purpura and IgA nephropathy23,24, conditions 
associated with deposition of IgA in the affected tissues24-2''. 
FMF is also associated with increased prevalence of 
spondyloarthropathy26, in which raised IgA was found to 
correlate with disease activity and was linked to bacterial 
infection of the gut27. The role of increased IgA level in 
FMF and its association with certain immunologic and 
rheumatologic manifestations of the disease is intriguing 
and is currently being investigated.
The results of the clinical, serological, and genetic analy­
sis in this study suggest that FMF and HIDS are 2 separate 
diseases, differing in their molecular basis, pathogenesis, 
clinical expression, response to treatment, and prognosis. 
How these 2 different entities share common features, such 
as an episodic nature and certain system and organ involve­
ment, remains to be elucidated.
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